Hot Investor Mandate 3: Life Sciences VC Arm of Large Czech Financial Group Seeks Early-Stage Investment Opportunities in All Sectors

22 Feb

An investment arm of a large, Czech Republic-based financial group that manages 10 sub-funds that total to $400M AUM, has a $22M fund through which the firm actively invests in early-stage life-science companies. The firm prefers to act as the first institutional investor – i.e. it deploys around $250 to $350,000 as initial investment and then provides follow-on investments for companies that achieve a number of milestones. The firm will consider opportunities globally, but mainly focuses its activities in North America and Europe.

The fund is sector agnostic and will consider all innovative technologies within the areas of therapeutics, medical devices, diagnostics, and healthcare IT. About 1/3 of the fund is dedicated to digital health technologies with special interest in the area of mental health. While the fund is mostly indication agnostic, it tends to avoid the over-crowded indications such as oncology/immune-oncology.

The firm is an active investor and takes a dedicated role in its portfolio of companies, providing them with resources and expertise to support company growth. The firm seeks to work with experienced management teams that are working on technology with strong market potential. The firm prefers to act as the lead investor but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: